Amivantamab Antibodies, Bispecific Drug Resistance, Neoplasm EGFR amplification EGFR protein, human EGFR triple mutation EGFR/MET dual inhibition Epidermal Growth Factor ErbB Receptors Humans L858R/T790M/G796S Lung Neoplasms Mutation Osimertinib esistance Protein Kinase Inhibitors Trogocytosis amivantamab bi-specific antibody bispecific antibody drug resistance epidermal growth factor epidermal growth factor receptor genetics human lung tumor mutation protein kinase inhibitor